{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:49:16Z","timestamp":1763552956321,"version":"3.45.0"},"reference-count":37,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Type 2 diabetes mellitus (T2DM) is a major metabolic disorder associated with progressive microvascular complications such as nephropathy, retinopathy, and neuropathy. Early detection of diabetic nephropathy (DN) remains challenging, as conventional markers such as urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) are influenced by non-renal factors and lack sensitivity for subclinical injury. Sirtuin 2 (SIRT2), a cytoplasmic NAD+-dependent deacetylase involved in oxidative stress and inflammatory regulation, has recently been implicated in renal pathophysiology. This study aimed to assess the relationship between serum SIRT2 levels and the presence of diabetic nephropathy and to evaluate its potential utility as a complementary biomarker reflecting early renal injury. Methods: In this single-center, cross-sectional study, 180 participants aged 18\u201380 years were enrolled: 60 healthy controls, 60 T2DM patients without nephropathy (T2DM \u2212 DN), and 60 T2DM patients with nephropathy (T2DM + DN). Serum SIRT2 concentrations were quantified using a validated ELISA. Group comparisons, multinomial logistic regression, and receiver operating characteristic (ROC) curve analyses were performed to assess associations between SIRT2 and renal indices (UACR and eGFR). Statistical significance was set at p &lt; 0.05. Results: Serum SIRT2 concentrations showed a progressive elevation across study groups (p &lt; 0.001), with median levels of 6.13 ng\/mL in healthy controls, 8.53 ng\/mL in T2DM \u2212 DN, and 33.19 ng\/mL in T2DM + DN. ROC analysis revealed good diagnostic performance for differentiating DN from healthy controls (AUC = 0.813, sensitivity 75%, and specificity 78.3%). Multivariable regression analysis identified SIRT2 as an independent correlate of DN after adjusting for metabolic and renal covariates (adjusted OR = 1.22, 95% CI 1.11\u20131.35, p &lt; 0.001). Conclusions: Serum SIRT2 levels were observed to increase in parallel with the presence and severity of diabetic nephropathy and remained independently associated with the condition after adjustment for conventional risk factors. These findings suggest that SIRT2 may serve as a feasible complementary biomarker reflecting renal injury processes not captured by traditional measures. Further longitudinal studies are warranted to clarify its prognostic significance and potential for clinical integration.<\/jats:p>","DOI":"10.3390\/jcm14228095","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:17:27Z","timestamp":1763551047000},"page":"8095","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Clinical Significance of Serum Sirtuin 2 in Diabetic Nephropathy: Evidence for a Potential Biomarker of Renal Injury"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4976-4771","authenticated-orcid":false,"given":"Ozgur","family":"Yilmaz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, Atakent Distr., Turgut Ozal Blvd., No: 46\/1, Kucukcekmece, 34303 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-0136","authenticated-orcid":false,"given":"Osman","family":"Erinc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, Atakent Distr., Turgut Ozal Blvd., No: 46\/1, Kucukcekmece, 34303 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5117-528X","authenticated-orcid":false,"given":"Murvet","family":"Algemi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Kanuni Sultan Suleyman Training and Research Hospital, 34303 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5609-9634","authenticated-orcid":false,"given":"Recep","family":"Demirci","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kanuni Sultan Suleyman Training and Research Hospital, 34303 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4236-1181","authenticated-orcid":false,"given":"Sengul Aydin","family":"Yoldemir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, Atakent Distr., Turgut Ozal Blvd., No: 46\/1, Kucukcekmece, 34303 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-4252","authenticated-orcid":false,"given":"Murat","family":"Akarsu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, Atakent Distr., Turgut Ozal Blvd., No: 46\/1, Kucukcekmece, 34303 Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"ref_1","first-page":"257","article-title":"Diabetic nephropathy as the cause of end-stage kidney disease reported on the medical evidence form CMS2728 at a single center","volume":"10","author":"Yuan","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ma, X., Liu, R., Xi, X., Zhuo, H., and Gu, Y. (2025). Global burden of chronic kidney disease due to diabetes mellitus, 1990\u20132021, and projections to 2050. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1513008"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100873","DOI":"10.1016\/j.xkme.2024.100873","article-title":"Healthcare Costs Across Diabetic Kidney Disease Stages: A Veterans Affairs Study","volume":"6","author":"Kim","year":"2024","journal-title":"Kidney Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Scilletta, S., Di Marco, M., Miano, N., Filippello, A., Di Mauro, S., Scamporrino, A., Musmeci, M., Coppolino, G., Di Giacomo Barbagallo, F., and Bosco, G. (2023). Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk. Biomolecules, 13.","DOI":"10.3390\/biom13050752"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shi, S., Ni, L., Gao, L., and Wu, X. (2022). Comparison of Nonalbuminuric and Albuminuric Diabetic Kidney Disease Among Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.871272"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.17925\/EE.2022.18.2.102","article-title":"Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria","volume":"18","author":"Viejo","year":"2022","journal-title":"TouchREV Endocrinol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4093\/dmj.2021.0329","article-title":"Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease","volume":"46","author":"Jung","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rico-Fontalvo, J., Aroca-Mart\u00ednez, G., Daza-Arnedo, R., Cabrales, J., Rodr\u00edguez-Yanez, T., Cardona-Blanco, M., Montejo-Hern\u00e1ndez, J., Rodelo Barrios, D., Pati\u00f1o-Pati\u00f1o, J., and Osorio Rodr\u00edguez, E. (2023). Novel Biomarkers of Diabetic Kidney Disease. Biomolecules, 13.","DOI":"10.3390\/biom13040633"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Joumaa, J.P., Raffoul, A., Sarkis, C., Chatrieh, E., Zaidan, S., Attieh, P., Harb, F., Azar, S., and Ghadieh, H.E. (2025). Mechanisms, Biomarkers, and Treatment Approaches for Diabetic Kidney Disease: Current Insights and Future Perspectives. J. Clin. Med., 14.","DOI":"10.3390\/jcm14030727"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13098-025-01726-4","article-title":"Decoding diabetic kidney disease: A comprehensive review of interconnected pathways, molecular mediators, and therapeutic insights","volume":"17","author":"Efiong","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tcb.2014.04.002","article-title":"NAD+ and sirtuins in aging and disease","volume":"24","author":"Imai","year":"2014","journal-title":"Trends Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1681\/ASN.2014030226","article-title":"SIRT2 Regulates LPS-Induced Renal Tubular CXCL2 and CCL2 Expression","volume":"26","author":"Jung","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41419-024-06833-0","article-title":"Mitochondrial metabolic reprogramming in diabetic kidney disease","volume":"15","author":"Fan","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jin, Q., Liu, T., Qiao, Y., Liu, D., Yang, L., Mao, H., Ma, F., Wang, Y., Peng, L., and Zhan, Y. (2023). Oxidative stress and inflammation in diabetic nephropathy: Role of polyphenols. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1185317"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hong, Y.A., Kim, J.E., Jo, M., and Ko, G.J. (2020). The Role of Sirtuins in Kidney Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186686"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12964-023-01442-4","article-title":"Sirtuins in kidney diseases: Potential mechanism and therapeutic targets","volume":"22","author":"Jin","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1093\/hmg\/ddx298","article-title":"The NAD+-dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes","volume":"26","author":"Lemos","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1074\/jbc.M113.537266","article-title":"Sirt2 deacetylase is a novel AKT binding partner critical for AKT activation by insulin","volume":"289","author":"Ramakrishnan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Xu, S.N., Wang, T.S., Li, X., and Wang, Y.P. (2016). SIRT2 activates G6PD to enhance NADPH production and promote leukemia cell proliferation. Sci. Rep., 6.","DOI":"10.1038\/srep32734"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.molcel.2011.04.028","article-title":"Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase","volume":"43","author":"Jiang","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kitada, M., Ogura, Y., Monno, I., and Koya, D. (2019). Sirtuins and Type 2 Diabetes: Role in Inflammation, Oxidative Stress, and Mitochondrial Function. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00187"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00018-024-05567-8","article-title":"Sirtuin 2 exacerbates renal tubule injury and inflammation in diabetic mice via deacetylation of c-Jun\/c-Fos","volume":"82","author":"Chen","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3892\/mmr.2024.13267","article-title":"TGF \u03b2\/Smad signaling in chronic kidney disease: Exploring post translational regulatory perspectives (Review)","volume":"30","author":"Li","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41419-023-06169-1","article-title":"SIRT2 alleviated renal fibrosis by deacetylating SMAD2 and SMAD3 in renal tubular epithelial cells","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Son, J., Park, J., Jeong, J.W., Lee, S.H., and Kim, J.E. (2025). SIRT2 inhibition attenuates myofibroblast transition through autophagy-mediated ciliogenesis in renal epithelial cells. Int. J. Biochem. Cell Biol., 181.","DOI":"10.1016\/j.biocel.2025.106754"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, R., Chang, R., Wang, H., Chen, J., Lu, C., Fan, K., Zhang, Y., Li, L., Yan, S., and Dong, H. (2025). Untargeted metabolomic and proteomic analysis implicates SIRT2 as a novel therapeutic target for diabetic nephropathy. Sci. Rep., 15.","DOI":"10.1038\/s41598-024-80492-1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1159\/000539886","article-title":"Urinary SIRT2 Reflects Kidney Injury in Type 2 Diabetes","volume":"49","author":"Dai","year":"2024","journal-title":"Kidney Blood Press. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Shetty, S., Suvarna, R., Awasthi, A., Bhojaraja, M.V., and Pappachan, J.M. (2025). Emerging Biomarkers and Innovative Therapeutic Strategies in Diabetic Kidney Disease: A Pathway to Precision Medicine. Diagnostics, 15.","DOI":"10.3390\/diagnostics15080973"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Harkin, C., Cobice, D., Brockbank, S., Bolton, S., Johnston, F., Strzelecka, A., Watt, J., Kurth, M.J., Lamont, J.V., and Fitzgerald, P. (2022). Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects: A Case-Control Study to Identify Potential Biomarkers of DN to Stratify Risk of Progression in T2D Patients. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.887237"},{"key":"ref_30","unstructured":"American Diabetes Association Professional Practice Committee (2024). 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S16\u2013S28."},{"key":"ref_31","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2023). KDIGO 2023 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 103, S1\u2013S150."},{"key":"ref_32","first-page":"177","article-title":"Nonalbuminuric diabetic kidney disease: A neglected entity","volume":"10","author":"MacIsaac","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bonifant, G., Davis, S.N., and Weir, M.R. (2025). Treatment of diabetes in patients with advanced chronic kidney disease or kidney failure. Nephrol. Dial. Transplant., Epub ahead of print.","DOI":"10.1093\/ndt\/gfaf083"},{"key":"ref_34","first-page":"884","article-title":"Tubular markers are associated with decline in kidney function in type 2 diabetes","volume":"42","author":"Nielsen","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/sj.ki.5002729","article-title":"Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review","volume":"73","author":"Coca","year":"2008","journal-title":"Kidney Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/ndt\/gfs058","article-title":"Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease","volume":"27","author":"Navaneethan","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Donate-Correa, J., Luis-Rodr\u00edguez, D., Mart\u00edn-N\u00fa\u00f1ez, E., Tagua, V.G., Hern\u00e1ndez-Carballo, C., Ferri, C., Rodr\u00edguez-Rodr\u00edguez, A.E., Mora-Fern\u00e1ndez, C., and Navarro-Gonz\u00e1lez, J.F. (2020). Inflammatory Targets in Diabetic Nephropathy. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020458"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8095\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:44:51Z","timestamp":1763552691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":37,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228095"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228095","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}